Italy Neurology Procedures Outlook to 2025 – Hydrocephalus Shunting Procedures, Neurovascular Thrombectomy Procedures, ICP Procedures and Others

2018-12-01
Price :
Published : Dec-2018
No. of Pages : 45

Italy Neurology Procedures Outlook to 2025 – Hydrocephalus Shunting Procedures, Neurovascular Thrombectomy Procedures, ICP Procedures and Others

Summary

GlobalData’s new report, Italy Neurology Procedures Outlook to 2025, provides key procedures data on the Italy Neurology Procedures. The report provides procedure volumes within market categories – Dura Substitute Procedures, Hydrocephalus Shunting Procedures, ICP Procedures, Intracranial Stenting Procedures, Neuromodulation Procedures, Neurovascular Accessory Procedures, Neurovascular Coiling Assist Procedures, Neurovascular Embolization Procedures and Neurovascular Thrombectomy Procedures

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology based models to estimate and forecast the procedure volumes. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the procedure volumes.

Scope

– Italy Neurology Procedures volumes by categories – Dura Substitute Procedures, Hydrocephalus Shunting Procedures, ICP Procedures, Intracranial Stenting Procedures, Neuromodulation Procedures, Neurovascular Accessory Procedures, Neurovascular Coiling Assist Procedures, Neurovascular Embolization Procedures and Neurovascular Thrombectomy Procedures.
– Projections for each of the market categories. Data is provided from 2015 and forecast to 2025.
– Develop business and investment strategies by identifying the key market categories expected to register strong growth in the near future.
– Develop market-entry and market expansion strategies.

Reasons to buy

– Develop business and investment strategies by identifying the key market segment expected to register strong growth in the near future.
– Develop market-entry and market expansion strategies.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Healthcare Industry Business Confidence Report 2019

Healthcare Industry Business Confidence Report 2019 Summary GlobalData's "Healthcare Industry Business Confidence Report 2019", examines executives' opinion about the business environment during 2019. It also highlights current economic conditions, supplier price variations, sales performance, industry and company growth prospects, spending models, and key priorities. Additionally, the report provides information categorized by region, and company size and type. The majority of respondents see the current global economic situation as stable or favorable. North American and Asia-Pacific economies were viewed as most favorable but respondents from these regions had less favorable views of the global economy. Factors such as reduced mortality, aging population, advances in biomedical engin......
$1950

Multiple Myeloma: Epidemiology Forecast to 2027

Multiple Myeloma: Epidemiology Forecast to 2027 Summary Multiple myeloma (MM) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C90.0) is a hematologic cancer that forms in a type of white blood cell called a plasma cell. In 2017, the 8MM had 81,380 diagnosed incident cases of MM. This is expected to increase to 103,272 diagnosed incident cases by 2027, at an Annual Growth Rate (AGR) of 2.69%. The increase is driven by the aging population in the 8MM. In 2017, the 8MM had 353,890 diagnosed prevalent cases of MM. This is expected to increase to 555,243 diagnosed prevalent cases by 2027, at an AGR of 5.69%. The US had the highest number of diagnosed incident and diagnosed prevalent cases of MM. The development of more effectiv......
$3995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Germany

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Germany". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Germany. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Germany. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house anal......
$1995

Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD) : Competitive Landscape to 2027

Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD): Competitive Landscape to 2027 Summary Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD) is one of the many complications associated with overall CKD. The systemic disorder is identified from high parathyroid hormone and disrupted K+/Ca2+ levels caused by a decreasing glomerular filtration rate (GFR) due to renal impairment. This report provides an assessment of the pipeline, clinical, and commercial landscape of CKD-MBD. Overall, GlobalData expects minimal changes to overall disease treatment, with exceptions being the launch of the novel NHE3 and novel CASR in the US and Japan markets respectively. Scope - Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type - Clini......
$3495

Gastrointestinal Disorders: Innovative Pipeline Offers Potential for First Approved Therapies in NASH and Celiac Disease

Gastrointestinal Disorders: Innovative Pipeline Offers Potential for First Approved Therapies in NASH and Celiac Disease Summary The burden of disease associated with gastrointestinal disorders is considerable with many of these disorders being highly prevalent. Additionally, many GI disorders are chronic in nature and are associated with significant impairments in quality of life including activity impairment and productivity loss. Despite this, many of these conditions are still incompletely understood and suboptimally managed. Therefore, there is a considerable unmet need for innovative new therapies in this area. This report assesses first-in-class innovation across the gastrointestinal therapy area, with a particular focus on four key indications: Crohn's disease, ulcerative colitis......
$6995

Chimeric Antigen Receptor Cell Therapy

Chimeric Antigen Receptor Cell Therapy Summary Chimeric antigen receptor (CAR) cell therapy is an immuno-oncology (IO) approach that has gained increasing momentum in the past few years, with the approval of two new therapies in 2017 (US) and 2018 (EU). Novartis' Kymriah (tisagenlecleucel) and Gilead Sciences' Yescarta (axicabtagene ciloleucel) demonstrated impressive efficacy, and have both been approved for diffuse large B-cell lymphoma (DLBCL), with Novartis' product approved for acute lymphocytic leukemia as well. Despite promising efficacy data, several challenges face the integration of CAR cell therapies into the clinic. Complex manufacturing can lead to delayed patient access, as currently approved therapies can take up to three weeks to manufacture. High toxicity is also a key c......
$7995

Company Profile: 23andMe

Company Profile: 23andMe Summary 23andMe is a personal genomics and biotechnology company that leverages machine learning technology to provide DNA analysis services. It also offers web-based interactive tools to individuals, helping them understand their own genetics information. Scope The report provides information and insights into 23andMe, including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into 23andMe's business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success ......
$350

Company Profile: Fitbit, Inc.

Company Profile: Fitbit, Inc. Summary Fitbit, Inc. (Fitbit) offers a range of connected health and fitness devices that monitors various health parameters like sleep duration, heart rate, BMI, calories burned, exercise routines, etc. Scope The report provides information and insights into Fitbit, Inc., including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into Fitbit business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success factors.......
$350

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – India

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in India. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of India. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

The State of the Microbiome

The State of the Microbiome Summary GlobalData's "The State of the Microbiome", report provides an assessment of how the pharmaceutical industry perceives the state of the microbiome, including the challenges associated with developing, launching, and manufacturing microbiome therapeutics as well as where opportunity remains to invest in the microbiome space. Scope - Microbiome investment - determine level of activity and investment in the development of microbiome therapeutics by therapy area - Identify the challenges associated with - Developing microbiome therapeutics - Launching microbiome therapeutics - Manufacturing microbiome therapeutics. Reasons to buy - Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with devel......
$1495
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy